Hepatobiliary cancers, version 2.2019: Featured updates to the NCCN Guidelines Guidelines

  


Authors: Benson, A. B. 3rd; D'Angelica, M. I.; Abbott, D. E.; Abrams, T. A.; Alberts, S. R.; Anaya, D. A.; Anders, R.; Are, C.; Brown, D.; Chang, D. T.; Cloyd, J.; Covey, A. M.; Hawkins, W.; Iyer, R.; Jacob, R.; Karachristos, A.; Kelley, R. K.; Kim, R.; Palta, M.; Park, J. O.; Sahai, V.; Schefter, T.; Sicklick, J. K.; Singh, G.; Sohal, D.; Stein, S.; Tian, G. G.; Vauthey, J. N.; Venook, A. P.; Hammond, L. J.; Darlow, S. D.
Title: Hepatobiliary cancers, version 2.2019: Featured updates to the NCCN Guidelines
Abstract: The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma. © 2019 Harborside Press. All rights reserved.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 17
Issue: 4
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2019-04-01
Start Page: 302
End Page: 310
Language: English
DOI: 10.6004/jnccn.2019.0019
PUBMED: 30959462
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064402472&doi=10.6004%2fjnccn.2019.0019&partnerID=40&md5=5809abcc61066a22a4eb322209b53362
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Anne Covey
    166 Covey
  2. Michael D'Angelica
    779 D'Angelica
Related MSK Work